Ormeloxifene is primarily used as a contraceptive but may also be effective for dysfunctional uterine bleeding and advanced breast cancer.

[8] It has a failure rate of about 1-2% with ideal use which is slightly less effective than found for combined oral contraceptive pills.

[13][14][15] It causes an asynchrony in the menstrual cycle between ovulation and the development of the uterine lining, although its exact mode of action is not well defined.

[9][17] Since 2018, Centchroman is provided free-of-cost to the women in India by the government under the brand name Chhaya.

[21] Ormeloxifene has been tested and licensed as a form of birth control, as well as a treatment for dysfunctional uterine bleeding.